Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-09

Reporting Person: Sofinnova Venture Partners X, L.P. (10% Owner)
Reporting Person: Sofinnova Management X, L.L.C. (10% Owner)
Reporting Person: Katabi Maha (10% Owner)
Reporting Person: POWELL MICHAEL (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Common Stock	C	1104209	—	Acquired	1104209	Direct
2021-02-09	Common Stock	C	1200228	—	Acquired	2304437	Direct
2021-02-09	Common Stock	P	450000	$20	Acquired	2754437	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Series C-1 Preferred Stock	$	C	1104209	Disposed		Common Stock (1104209)	Direct
2021-02-09	Series C-2 Preferred Stock	$	C	1200228	Disposed		Common Stock (1200228)	Direct

Footnotes

F1: The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

F3: The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.